Swiss drugmakers Novartis and Roche ditch some diversity programs on U.S. concerns

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse panels for U.S. hiring, the latest companies acting to avoid penalties from recent U.S. executive orders